Treatment of HeartMate III-LVAD driveline infection by negative pressure wound therapy: Result of our case series.


Journal

The International journal of artificial organs
ISSN: 1724-6040
Titre abrégé: Int J Artif Organs
Pays: United States
ID NLM: 7802649

Informations de publication

Date de publication:
Nov 2021
Historique:
pubmed: 25 9 2021
medline: 3 11 2021
entrez: 24 9 2021
Statut: ppublish

Résumé

Driveline infection is one of the most frequent complications following left ventricular assist device (LVAD) treatment and there is no consensus for its management. The standard approach to treat foreign-body infection is complete device ablation, which is not always feasible and therefore not an elected method for LVAD driveline infections. Here we share the results from a series of cases successfully treated for driveline infection by negative pressure wound therapy (NPWT) therapy. Between 2016 and 2020, five male patients were hospitalized in our unit with a driveline infection of HeartMate III-LVAD

Identifiants

pubmed: 34558333
doi: 10.1177/03913988211047250
pmc: PMC8559168
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

912-916

Références

Ann Transl Med. 2015 Nov;3(20):306
pubmed: 26697466
Int Wound J. 2011 Jun;8(3):229-36
pubmed: 21401883
Circulation. 2013 Feb 12;127(6):691-702
pubmed: 23315371
Artif Organs. 2019 May;43(5):448-457
pubmed: 30357880
Clin Infect Dis. 2013 Nov;57(10):1438-48
pubmed: 23943820
Ann Thorac Surg. 2012 Nov;94(5):1381-6
pubmed: 22818961
J Heart Lung Transplant. 2018 Oct;37(10):1155-1168
pubmed: 30293612
J Card Fail. 2019 Oct;25(10):795-802
pubmed: 31454687
ASAIO J. 2006 May-Jun;52(3):354-6
pubmed: 16760728
ASAIO J. 2014 Nov-Dec;60(6):613-6
pubmed: 25072552
ASAIO J. 2018 May/Jun;64(3):287-294
pubmed: 29095732
Ann Thorac Surg. 2007 Aug;84(2):515-20
pubmed: 17643627
Plast Reconstr Surg. 2001 Feb;107(2):364-73
pubmed: 11214051
J Thorac Dis. 2018 Jun;10(Suppl 15):S1703-S1710
pubmed: 30034842
Ann Thorac Surg. 2015 Sep;100(3):884-9
pubmed: 26095106

Auteurs

Mustafa Cikirikcioglu (M)

Division of Cardiovascular Surgery, Department of Surgery, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Kevin Ponchant (K)

Division of Cardiovascular Surgery, Department of Surgery, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Nicolas Murith (N)

Division of Cardiovascular Surgery, Department of Surgery, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Philippe Meyer (P)

Division of Cardiology, Department of Internal Medicine, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Nurcan Yilmaz (N)

Division of Cardiovascular Surgery, Department of Surgery, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Christoph Huber (C)

Division of Cardiovascular Surgery, Department of Surgery, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH